摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

水合钠 | 159536-30-8

中文名称
水合钠
中文别名
钠,水合物
英文名称
sodium(water)3
英文别名
sodium trihydrate;Sodium monohydrate
水合钠化学式
CAS
159536-30-8
化学式
3H2O*Na
mdl
——
分子量
77.0356
InChiKey
NASFKTWZWDYFER-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.21
  • 重原子数:
    2
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    3-(6-acetylamino-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-phenyl-2-propenamide 、 水合钠二氯甲烷Sodium sulfate-III 作用下, 以 甲醇 为溶剂, 反应 5.0h, 以to give 696 mg (80% yield) of the title compound的产率得到3-(6-amino-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-phenyl-2-propenamide
    参考文献:
    名称:
    Azaindole derivatives, process for their preparation, and their use as antitumor agents
    摘要:
    化合物1H-吡咯并[2,3-b]吡啶,其化学式为(I):其中R为氢原子或卤素原子,或从以下组中选择的基团:—CN,—OH,—OCOR4,—(CH2)nNH2,—(CH2)nNHR4,—(CH2)nNHCOR4,—(CH2)nNHCONR4R5,—(CH2)nNHCOOR4或—(CH2)nNHSO2R4,其中n为0或1,R4和R5如规范中所述;R1为氢原子或可选择性取代的烷基基团;R2为可选择性取代的烷基或芳基基团;R3为氢原子或从以下组中选择的基团:—CONR4R5,—COOR4,—CONHOR4,—SO2NHR4,烷基磺酰氨基甲酰基或全氟烷基磺酰氨基甲酰基;或其药学上可接受的盐。这些化合物可用于治疗与细胞依赖性激酶活性改变相关的细胞增殖性疾病。
    公开号:
    US06486322B1
  • 作为试剂:
    描述:
    Trans-6-pentafluoroethyl-2,2-bisfluoromethyl-3,4-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyran-3-ol 、 甲基磺酰氯三乙胺二氯甲烷 、 resultant residue 、 四氢呋喃水合钠 、 ice 、 Ice water 作用下, 以 四氢呋喃 为溶剂, 反应 74.0h, 以to obtain 0.09 g of 6-pentafluoroethyl-2,2-bisfluoromethyl-4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyran的产率得到6-pentafluoroethyl-2,2-bisfluoromethyl-4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyran
    参考文献:
    名称:
    Benzopyran derivatives
    摘要:
    一种新型苯并吡喃和苯并噁嗪衍生物,其一般式为:##STR1## 其中R.sub.1和R.sub.2代表较低的卤代烷基,R.sub.3代表氢原子,R.sub.4代表杂环基或A--O--,其中A代表环状结构,R.sub.5和R.sub.6代表较低的卤代烷基,X代表.dbd.N--,N.fwdarw.O等。这些化合物表现出K.sup.+通道开放激活作用,可广泛用作抗哮喘药物、抗癫痫药物等。
    公开号:
    US05614633A1
点击查看最新优质反应信息

文献信息

  • Carbapenem antibacterial compounds, compositions containing such
    申请人:Merck & Co., Inc.
    公开号:US05496816A1
    公开(公告)日:1996-03-05
    Carbapenems of the formula: ##STR1## are disclosed as useful antibacterial agents. Pharmaceutical compositions and methods of use are also disclosed.
    公开了化学式为:##STR1## 的碳青霉烯类化合物作为有用的抗菌剂。同时还公开了药物组合物和使用方法。
  • Cephalosporin derivatives
    申请人:Boehringer Ingelheim GmbH
    公开号:US04415566A1
    公开(公告)日:1983-11-15
    Penicillins and cephalosporins of the formula ##STR1## wherein A is phenyl, 4-hydroxyphenyl, cyclohexyl, cyclohene-1-yl, cyclohexa-1,4-diene-1-yl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl or 3,4-disubstituted phenyl, where the substituents, which may be identical to or different from each other, are each chlorine, hydroxyl or methoxy; R.sub.1 is an unsubstituted or substituted 5- or 6-membered heterocycle comprising carbon atoms and 1 to 4, preferably 1 to 2, identical or different heteroatoms such as oxygen, sulfur or nitrogen; n is 0 or 1; X is ##STR2## D is hydrogen, hydroxyl, acetoxy, aminocarbonyloxy, pyridinium, aminocarbonyl-pyridinium or S-Het, where Het is 1-methyl-tetrazol-5-yl, tetrazol-5-yl, 3-methyl-1,2,4-thiadiazol-5-yl, 1,2,4-triadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-methyl-1,3,4-thiadiazol-5-yl, 2-methylamino-1,3,4-thiadiazol-5-yl, 2-dimethylamino-1,3,4-thiadiazol-5-yl, 2-formylamino-1,2,4-thiadiazol-5-yl , 2-acetylamino-1,3,4-thiadiazol-5-yl, 2-methyl-1,3,4-oxadiazol-5-yl, 1,2,3-triazol-4-yl or 1,2,4-triazol-3-yl; and E is hydrogen or a protective group which is easily removable in nitro or in vivo, especially an ester-forming group which can be removed under mild conditions by hydrogenation or hydrolysis or other treatments, or an ester-forming group which can easily be split off in the living organism; and, when E is hydrogen, their non-toxic, pharmacologically acceptable salts thereof, such as their alkali metal or alkaline earth metal salts, especially the sodium, potassium, magnesium or calcium salts; their ammonium salts; or their organic amine salts, especially the triethylamine or dicyclohexylamine salts. The compounds are useful as antibiotics.
    公式为##STR1##的青霉素和头孢菌素,其中A是苯基、4-羟基苯基、环己基、环己烯-1-基、环己-1,4-二烯-1-基、2-噻吩基、3-噻吩基、2-呋喃基、3-呋喃基或3,4-二取代苯基,其中取代基可能相同或不同,分别是氯、羟基或甲氧基;R.sub.1是未取代或取代的5或6元杂环,包括碳原子和1至4个,优选1至2个相同或不同的杂原子,例如氧、硫或氮;n为0或1;X为##STR2##D为氢、羟基、乙酰氧基、氨基羰基氧基、吡啶铵、氨基羰基吡啶铵或S-Het,其中Het是1-甲基四唑-5-基、四唑-5-基、3-甲基-1,2,4-噻二唑-5-基、1,2,4-三唑-5-基、1,3,4-噻二唑-5-基、2-甲基-1,3,4-噻二唑-5-基、2-甲氨基-1,3,4-噻二唑-5-基、2-二甲氨基-1,3,4-噻二唑-5-基、2-甲酰氨基-1,2,4-噻二唑-5-基、2-乙酰氨基-1,3,4-噻二唑-5-基、2-甲基-1,3,4-噻唑-5-基、1,2,3-三唑-4-基或1,2,4-三唑-3-基;E为氢或易于在硝基或体内去除的保护基,特别是可以在温和条件下通过氢化或水解或其他处理去除的酯形成基,或者可以在生物体内容易分解的酯形成基;当E为氢时,其非毒性、药理学上可接受的盐,例如其碱金属或碱土金属盐,特别是钠、钾、镁或钙盐;它们的铵盐;或它们的有机胺盐,特别是三乙胺或二环己基胺盐。这些化合物可用作抗生素。
  • Method of producing polycarbosilane using zeolite as catalyst
    申请人:Park Sik Hong
    公开号:US20050014964A1
    公开(公告)日:2005-01-20
    The present invention is related to a method of producing polycarbosilane by heating polydimethylsilane at low pressure within the range of 320˜450° C. using zeolite having the Si/Al or Si/B ratio of 1˜200 as catalyst. This invention uses a zeolite with the structure of ZSM-5, ZSM-11, ZSM-12, zeolite X and zeolite Y, which has the Si/Al or Si/B ratio of 1˜200, as catalyst. When polycarbosilane is produced using a specific zeolite as catalyst, Si/Al or Si/B ratio can be adjusted at any proportion, enabling acidity control of catalyst, and therefore the molecular weight of final products can be easily controlled and the product yield can be improved, compared to conventional solid acid catalysts.
    本发明涉及一种通过在低压下使用具有Si/Al或Si/B比为1-200的沸石作为催化剂,在320~450℃范围内加热聚二甲基硅烷以生产聚碳硅烷的方法。本发明使用具有ZSM-5、ZSM-11、ZSM-12、沸石X和沸石Y结构的沸石作为催化剂,其Si/Al或Si/B比为1-200。当使用特定的沸石作为催化剂生产聚碳硅烷时,Si/Al或Si/B比可以按任意比例调整,从而实现催化剂的酸度控制,因此可以轻松控制最终产品的分子量并提高产品产量,相比传统的固体酸催化剂而言。
  • Medicinal compositions having improved absorbability
    申请人:——
    公开号:US20040053972A1
    公开(公告)日:2004-03-18
    An HER2 inhibitor having an average particle size of about 3 &mgr;m or less or a composition containing the same which has improved HER2 inhibitor-absorbability.
    一种平均粒径约为3μm或更小的HER2抑制剂,或含有该HER2抑制剂并具有改进的HER2抑制剂吸收性的组合物。
  • 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
    申请人:Pharmacia & Upjohn S.p.A
    公开号:US06218418B1
    公开(公告)日:2001-04-17
    Compounds which are 3-amino-pyrazole derivatives represented by formula (I): where R is a C3-C6 cycloalkyl group, which may optionally be substituted by a straight or branched C1-C6 alkyl group, and R1 is a straight or branched C1-C6 alkyl group or a C2-C4 alkenyl, cycloalkyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl and arylalkenyl, which may be optionally substituted; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.
    化合物是以公式(I)表示的3-氨基吡唑衍生物,其中R是C3-C6环烷基,可以选择地被直链或支链C1-C6烷基取代,而R1是直链或支链C1-C6烷基或C2-C4烯基,环烷基,芳香基,芳香基烷基,芳香基羰基,芳香基氧烷基和芳香基烯基,可以选择地被取代; 或其药学上可接受的盐。这些化合物可用于治疗癌症,细胞增殖性疾病,阿尔茨海默病,病毒感染,自身免疫疾病或神经退行性疾病。
查看更多